MX2008010879A - Composiciones farmaceuticas de sodio de fluvastatina. - Google Patents
Composiciones farmaceuticas de sodio de fluvastatina.Info
- Publication number
- MX2008010879A MX2008010879A MX2008010879A MX2008010879A MX2008010879A MX 2008010879 A MX2008010879 A MX 2008010879A MX 2008010879 A MX2008010879 A MX 2008010879A MX 2008010879 A MX2008010879 A MX 2008010879A MX 2008010879 A MX2008010879 A MX 2008010879A
- Authority
- MX
- Mexico
- Prior art keywords
- fluvastatin
- fluvastatin sodium
- stable
- composition
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen diversas composiciones de fluvastatina y métodos para prepararlas. Un ejemplo es una composición farmacéutica de liberación controlada que comprende fluvastatina y por lo menos un polímero hidrófilo no iónico, en donde la composición está sustancialmente libre de hidroxipropil metilcelulosa. Otro ejemplo es una composición farmacéutica estable que comprende fluvastatina, preferentemente sodio de fluvastatina en donde la composición está sustancialmente libre de un agente de estabilización de alcalinización. Otro ejemplo es una formulación farmacéutica de liberación controlada estable, que comprende fluvastatina, preferentemente sodio de fluvastatina, que es estable con un contenido de agua superior al 3,5 por ciento en peso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77652606P | 2006-02-24 | 2006-02-24 | |
PCT/US2007/005076 WO2007100822A2 (en) | 2006-02-24 | 2007-02-23 | Fluvastatin sodium pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008010879A true MX2008010879A (es) | 2008-10-27 |
Family
ID=38038960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008010879A MX2008010879A (es) | 2006-02-24 | 2007-02-23 | Composiciones farmaceuticas de sodio de fluvastatina. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080033030A1 (es) |
EP (1) | EP1825847A3 (es) |
JP (1) | JP2009527577A (es) |
KR (1) | KR20080094837A (es) |
CN (1) | CN101426478A (es) |
BR (1) | BRPI0708191A2 (es) |
CA (1) | CA2642195A1 (es) |
IL (1) | IL193358A0 (es) |
MX (1) | MX2008010879A (es) |
RU (1) | RU2008136767A (es) |
WO (1) | WO2007100822A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2402865T3 (es) * | 2006-05-12 | 2013-05-09 | Pharmathen S.A. | Formulación farmacéutica que contiene fluvastatina |
GB0713707D0 (en) * | 2007-07-13 | 2007-08-22 | Generics Uk Ltd | Stable compositions |
FR2938433B1 (fr) * | 2008-11-19 | 2011-09-09 | Francois Fauran | Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation |
CN102309452B (zh) * | 2011-09-14 | 2013-01-23 | 海南美大制药有限公司 | 氟伐他汀钠脂质体固体制剂 |
CN102805739B (zh) * | 2012-04-10 | 2013-08-14 | 宋芸 | 氟伐他汀钠缓释包衣滴丸及其制备方法 |
US10376470B2 (en) * | 2012-05-01 | 2019-08-13 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
RU2591079C2 (ru) * | 2014-12-10 | 2016-07-10 | Александр Владимирович Диковский | Фармацевтическая композиция статинов с пребиотиком для терапии гиперхолестеринемии и гиперлипидимии |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
SE9603667D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
GB9703388D0 (en) * | 1997-02-18 | 1997-04-09 | Sandoz Yakuhin K K Tokyo Sykk | Organic compounds |
CA2216215A1 (en) * | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
IE970731A1 (en) * | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
US20020169145A1 (en) * | 1998-10-14 | 2002-11-14 | Rajen Shah | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
CO5140079A1 (es) * | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP2382970B1 (en) * | 2000-04-10 | 2013-01-09 | Teva Pharmaceutical Industries, Ltd. | Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids or 7-Substituted-3,5-Dihydroxyheptenoic Acids |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
SI1292293T1 (en) * | 2000-06-09 | 2004-06-30 | LEK farmacevtska dru�ba d.d. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
US6806290B2 (en) * | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
DE10316087A1 (de) * | 2003-04-08 | 2004-11-11 | Ratiopharm Gmbh | Polymorphstabilisierung von Fluvastatin-Natrium in Pharmazeutischen Formulierungen |
CN1809342A (zh) * | 2003-06-25 | 2006-07-26 | 诺瓦提斯公司 | 含有氟伐他汀和羧甲纤维素钙的片剂 |
JP3944494B2 (ja) * | 2003-06-25 | 2007-07-11 | ノバルティス アクチエンゲゼルシャフト | フルバスタチン含有錠剤 |
US6890941B1 (en) * | 2003-12-03 | 2005-05-10 | Procaps S.A. | Compositions containing HMG Co-A reductase inhibitors and policosanol |
US20070275996A1 (en) * | 2003-12-16 | 2007-11-29 | Michele Bortolini | Use of Statins For The Treatment Of Metabolic Syndrome |
KR100598326B1 (ko) * | 2004-04-10 | 2006-07-10 | 한미약품 주식회사 | HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
CA2568542A1 (en) * | 2004-05-27 | 2005-12-08 | Dexcel Pharma Technologies Ltd. | Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins |
WO2006037348A1 (en) * | 2004-10-01 | 2006-04-13 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and a statin |
WO2006105806A1 (en) * | 2005-04-07 | 2006-10-12 | Miso Sabovic | Delaying the ageing process and disorders caused by ageing |
RS20070511A (en) * | 2005-06-29 | 2009-01-22 | Panacea Biotec Ltd., | Modified release pharmaceutical compositions and processes thereof |
EP1818050A1 (de) * | 2006-02-10 | 2007-08-15 | Stada Arzneimittel Ag | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor |
-
2007
- 2007-02-23 WO PCT/US2007/005076 patent/WO2007100822A2/en active Application Filing
- 2007-02-23 US US11/710,232 patent/US20080033030A1/en not_active Abandoned
- 2007-02-23 RU RU2008136767/15A patent/RU2008136767A/ru not_active Application Discontinuation
- 2007-02-23 EP EP07250774A patent/EP1825847A3/en not_active Withdrawn
- 2007-02-23 KR KR1020087022725A patent/KR20080094837A/ko not_active Application Discontinuation
- 2007-02-23 JP JP2008556479A patent/JP2009527577A/ja active Pending
- 2007-02-23 CN CNA200780014499XA patent/CN101426478A/zh active Pending
- 2007-02-23 CA CA002642195A patent/CA2642195A1/en not_active Abandoned
- 2007-02-23 BR BRPI0708191-0A patent/BRPI0708191A2/pt not_active IP Right Cessation
- 2007-02-23 MX MX2008010879A patent/MX2008010879A/es unknown
-
2008
- 2008-08-10 IL IL193358A patent/IL193358A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007100822A3 (en) | 2008-02-21 |
RU2008136767A (ru) | 2010-03-27 |
US20080033030A1 (en) | 2008-02-07 |
IL193358A0 (en) | 2009-05-04 |
CN101426478A (zh) | 2009-05-06 |
KR20080094837A (ko) | 2008-10-24 |
CA2642195A1 (en) | 2007-09-07 |
EP1825847A2 (en) | 2007-08-29 |
BRPI0708191A2 (pt) | 2012-05-29 |
WO2007100822A2 (en) | 2007-09-07 |
EP1825847A3 (en) | 2008-01-23 |
JP2009527577A (ja) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2008010879A (es) | Composiciones farmaceuticas de sodio de fluvastatina. | |
WO2007048219A3 (en) | Sustained drug release composition | |
MX2009013832A (es) | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. | |
PE20100265A1 (es) | Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion | |
TW200608975A (en) | Pharmaceutical compositions | |
AR065039A1 (es) | Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso | |
NO20076288L (no) | Farmasoytiske sammensetninger innbefattende imatinib og et frigivningssinkende middel | |
AR080242A1 (es) | Composiciones veterinarias. usos. | |
NZ585219A (en) | Fast release solid formulation, preparation and use thereof | |
NZ708247A (en) | Hyaluronic acid based formulations | |
EP3895700A3 (en) | Pharmaceutical compositions comprising iron oxy-hydroxide | |
MX2007008141A (es) | Composicion farmaceutica de sustancias labiles en medio acido. | |
MY149911A (en) | Methods for administering long-lasting hypoglycemic agents | |
MX2010005013A (es) | Composiciones intranasales. | |
MX2008013040A (es) | Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1. | |
BRPI0606373A2 (pt) | composição de xarope compreendendo dexibuprofeno como ingrediente ativo e método para a preparação da mesma | |
UA95224C2 (ru) | Антацидная фармацевтическая композиция в порошковой форме, фармацевтическое средство, ее содержащее, и способ ее получения | |
MX2010006215A (es) | Derivados de piperazina y su uso como moduladores del receptor de leptina. | |
MX2010003594A (es) | Formas cristalinas de sal sodica de dmxaa. | |
MX2010006216A (es) | Nuevos compuestos iii. | |
BRMU8603015U (pt) | agente farmacêutico contendo hialuronano como componente ativo | |
WO2009008004A3 (en) | Sustained release formulations of divalproex sodium | |
MX2010004072A (es) | Composicion farmaceutica de orlistat. | |
UA94275C2 (ru) | Фармацевтическая композиция, которая содержит по крайней мере один активный наркотический или психотропный компонент, назначенный способ введения которых в организм тяжело поддается изменению | |
NO20073850L (no) | Farmasoytisk polymersammensetning for oral kontrollert frigivelsesavlevering av terbutalinsulfat |